Table 2 Resistant mechanism, individual therapy strategy and efficacy in PG
Rsistance mechanism | Drugs | Number | ORR | DCR | PFS (m) |
|---|---|---|---|---|---|
MET amplification | MET plus EGFR-TKIs | 27 | 40.7% | 87.7% | 4.2 |
SCLC transformation | Etoposide plus platinum or carboplatin | 16 | 37.5% | 75.0% | 3.9 |
BRAF mutation | Dabrafenib, trametinib and EGFR-TKIs, | 3 | 33.3% | 33.3% | 2.9 |
ERBB2 amplification | Trastuzumab, chemotherapy and EGFR-TKIs | 4 | 0% | 100% | - |
RET fusion | LOXO-292 plus EGFR-TKIs | 1 | 0% | 0% | 0.9 |
T790M-trans-C797S | the 1st and 3rd EGFR-TKIs | 2 | 0% | 50% | 0.7 |